<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02170584</url>
  </required_header>
  <id_info>
    <org_study_id>1160.5</org_study_id>
    <nct_id>NCT02170584</nct_id>
  </id_info>
  <brief_title>Tolerability of BIBR 953 ZW IV and Bioavailability of BIBR 1048 Tablet and Solution in Healthy Males</brief_title>
  <official_title>Tolerability of Single Rising Doses of 0.1 mg, 1 mg, and 5 mg BIBR 953 ZW IV (Placebo-controlled in Each Dose Group; Substudy 1) and Absolute and Relative Bioavailability of 100mg BIBR 1048 Tablet and of Solution and of 1 mg or 5 mg BIBR 953 ZW IV (Randomized, Three-way Crossover; Substudy 2).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Two substudies to assess (1) the tolerability of BIBR 953 ZW intravenous infusion at 0.1, 1&#xD;
      and 5 mg BIBR 953 ZW and (2) the absolute bioavailability of 100mg BIBR 1048 administered as&#xD;
      'acid free' tablet formulation (TF1) and (3) the bioavailability of the 100 mg tablet of BIBR&#xD;
      1048 relative to the tartaric acid solution of 100 mg dose strength and (4) the absolute&#xD;
      bioavailability of the 100 mg tartaric acid solution of BIBR 1048 MS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <primary_completion_date type="Actual">March 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-inf (Area under the plasma concentration-time curve extrapolated to infinity)</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-tf (Area under the plasma concentration-time curve up to the last quantifiable plasma concentration)</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (Maximum plasma concentration after oral administration)</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative urinary excretion of BIBR 953 ZW administered intravenously</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in activated partial thromboplastin time (aPTT )</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in prothrombin time (PT)</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C29 (Plasma concentration of BIBR 953 ZW at 29 minutes after the start of the 30 min. infusion)</measure>
    <time_frame>29 minutes after start of infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 (terminal half-life)</measure>
    <time_frame>up to 48 hours after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLtot (total clearance of drug from plasma)</measure>
    <time_frame>up to 48 hours after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLren (renal clearance from plasma)</measure>
    <time_frame>up to 48 hours after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTdisp (Mean time of residence of drug molecules in the body after intravascular administration)</measure>
    <time_frame>up to 48 hours after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss (apparent volume of distribution at steady state)</measure>
    <time_frame>up to 48 hours after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz (Apparent volume of distribution during the terminal elimination phase)</measure>
    <time_frame>up to 48 hours after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTtot (total mean residence time)</measure>
    <time_frame>up to 48 hours after oral administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLtot/F (total clearance after oral administration)</measure>
    <time_frame>up to 48 hours after oral administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time to reach the peak plasma concentration)</measure>
    <time_frame>up to 48 hours after oral administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F (apparent volume of distribution of the terminal elimination phase after oral administration)</measure>
    <time_frame>up to 48 hours after oral administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in Ecarin clotting time (ECT)</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in thrombin time (TT)</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in vital signs (systolic and diastolic blood pressure, pulse rate)</measure>
    <time_frame>up to 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in electrocardiogram</measure>
    <time_frame>up to 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence of adverse events</measure>
    <time_frame>up to 1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BIBR 953 ZW IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBR 1048 MS oral solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBR 1048 MS tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBR 953 ZW IV Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 953 ZW IV</intervention_name>
    <arm_group_label>BIBR 953 ZW IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048 MS tablet</intervention_name>
    <arm_group_label>BIBR 1048 MS tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048 MS oral solution</intervention_name>
    <arm_group_label>BIBR 1048 MS oral solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 953 ZW IV Placebo</intervention_name>
    <arm_group_label>BIBR 953 ZW IV Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subjects as determined by results of screening&#xD;
&#xD;
          -  Signed written informed consent in accordance with GCP and local legislation&#xD;
&#xD;
          -  Age ≥ 18 and ≤ 50 years&#xD;
&#xD;
          -  Broca ≥ - 20% and ≤ + 20%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any findings of the medical examination (including blood pressure, pulse rate and ECG)&#xD;
             deviating from normal and of clinical relevance&#xD;
&#xD;
          -  History or current gastrointestinal, hepatic, renal, respiratory, cardiovascular,&#xD;
             metabolic, immunologic, hormonal disorders&#xD;
&#xD;
          -  History of orthostatic hypotension, fainting spells and blackouts&#xD;
&#xD;
          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders&#xD;
&#xD;
          -  Chronic or relevant acute infections&#xD;
&#xD;
          -  History of&#xD;
&#xD;
               -  allergy/hypersensitivity (including drug allergy) which is deemed relevant to the&#xD;
                  trial as judged by the investigator&#xD;
&#xD;
               -  any bleeding disorder including prolonged or habitual bleeding&#xD;
&#xD;
               -  other hematologic disease&#xD;
&#xD;
               -  cerebral bleeding (e.g. after a car accident)&#xD;
&#xD;
               -  commotio cerebri&#xD;
&#xD;
          -  Intake of drugs with a long half-life (&gt;24 hours) within 1 month prior to&#xD;
             administration&#xD;
&#xD;
          -  Use of any drugs which might influence the results of the trial within 10 days prior&#xD;
             to administration or during trial&#xD;
&#xD;
          -  Participation in another trial with an investigational drug within 2 months prior to&#xD;
             administration or during trial&#xD;
&#xD;
          -  Smoker (&gt; 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from&#xD;
             smoking on study days&#xD;
&#xD;
          -  Alcohol abuse (&gt; 60 g/day)&#xD;
&#xD;
          -  Drug abuse&#xD;
&#xD;
          -  Blood donation within 1 month prior to administration or during the trial&#xD;
&#xD;
          -  Excessive physical activities within 5 days prior to administration or during the&#xD;
             trial&#xD;
&#xD;
          -  Any laboratory value outside the clinically accepted reference range&#xD;
&#xD;
          -  History of any familial bleeding disorder&#xD;
&#xD;
          -  Thrombocytes &lt; 150000/µl&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1160/1160.5_U01-1807.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

